‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ...
Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26
– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data...
Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today...
- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo ...
2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.
- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized...
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...